Cannabis Report
Home > Boards > US OTC > Biotechs > CYTODYN INC (CYDY)

I'll also add that the additional ask regarding

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
BlackDoggie Member Profile
 
Followed By 9
Posts 581
Boards Moderated 0
Alias Born 02/17/17
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 6/22/2018 5:02:40 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 6/15/2018 7:49:45 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/15/2018 7:44:52 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2018 6:04:19 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2018 6:03:52 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2018 5:59:49 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2018 5:59:49 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2018 5:57:13 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2018 5:56:30 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2018 5:56:05 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2018 5:55:37 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2018 5:54:17 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/7/2018 4:24:25 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 5/22/2018 8:16:33 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/22/2018 7:46:52 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 5/22/2018 7:45:17 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 5/8/2018 4:06:32 PM
Proxy Soliciting Materials (revised) (prer14a) Edgar (US Regulatory) - 5/4/2018 10:54:38 AM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 4/26/2018 5:09:17 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/11/2018 6:09:06 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 4/9/2018 4:34:49 PM
Amended Tender Offer Statement by Issuer (sc To-i/a) Edgar (US Regulatory) - 3/26/2018 5:27:48 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/26/2018 5:25:36 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/26/2018 8:02:44 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 3/26/2018 6:02:12 AM
BlackDoggie   Friday, 11/10/17 11:37:33 AM
Re: BlackDoggie post# 18097
Post # of 23861 
I'll also add that the additional ask regarding patients for safety data may appear out of line with that reasoning at first blush. However, if I'm the FDA, and I'm agreeing to consider labeling more broadly than for a very small subset of very sick patients, I might want more safety data to justify it. Basically, if the company wants to market the drug (via the combo application) to a patient population that is less gravely ill than the patients they were originally restricted to, then the FDA might reasonably want more assurance that the drug is safe to offer to patients who may have options.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist